Skip to main content
Clinical Trials/CTRI/2025/09/094385
CTRI/2025/09/094385Not yet recruitingPhase 2

Effect of Gel Containing Plumbago Zeylanica in Mild to Moderate Knee Osteoarthritis –A Single Armed Open Label Pilot Clinical Trial

ICMR Belgaum1 site in 1 country30 target enrollmentStarted: November 10, 2025Last updated:

Trial Snapshot

Phase
Phase 2
Status
Not yet recruiting
Sponsor
Enrollment
30
Locations
1
Primary Endpoint
Pain (VAS) Tenderness Shotha swelling Inflammation Stabdata Stiffness walking velocity

Study Overview

Brief Summary

Effect of Gel Containing Plumbago Zeylanica in Mild to Moderate Knee Osteoarthritis A Single Armed Open Label Pilot Clinical Trial Objectives To evaluate the efficacy of Plumbago zeylanica gel as topical application in mild to moderate Knee Osteoarthritis in pain To assess the safety of Plumbago zeylanica gel as topical application in mild to moderate Knee Osteoarthritis 

Single centric Single Group clinical conditions having pain and inflammation with Pretest and Posttest design

30 patients with knee osteoarthritis meeting all inclusion/exclusion criteria will be included in the study

Trial medication Twice in a Day for a period of 7days Gel Containing Plumbago Zeylanica This will be applied at the site of pain

Follow-up will be on 0th & 8th day

Study Design

Study Type
Interventional
Allocation
Na
Masking
None

Eligibility Criteria

Ages
30.00 Year(s) to 70.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • Mild and Moderate cases of knee osteoarthritis Willing to give consent for participating in the study Patients who are currently on analgesics NSAID will be given a washout period of 8 days prior to recruitment.

Exclusion Criteria

  • Patients having severe knee osteoarthritis Those who are suffering from dermatitis or had a history of dermatitis Pregnant and lactating women Any other conditions which in the opinion of investigator will place the subject at risk or will influence the conduct of study or interpretation of results.

Outcomes

Primary Outcomes

Pain (VAS) Tenderness Shotha swelling Inflammation Stabdata Stiffness walking velocity

Time Frame: 0th Day. 7th Day

Secondary Outcomes

  • Changes in following parameters between day 0day 8 day in CBC, LFT, RFT

Investigators

Sponsor
ICMR Belgaum
Sponsor Class
Government funding agency
Responsible Party
Principal Investigator
Principal Investigator

Dr Pradeep L Grampurohit

KAHERs Shri B M K Ayurveda Mahavidyalaya

Study Sites (1)

Loading locations...

Similar Trials

Role of Ayurveda gel in Knee joint pain | Clinical Trial